Multiple Myeloma | Specialty

Dr. Costello on Treatment Selection Considerations in Multiple Myeloma

November 10th 2020

Caitlin Costello, MD, discusses treatment selection considerations in multiple myeloma.

CAR T-Cell Therapy for Multiple Myeloma: What Community Oncologists Need to Know

November 10th 2020

The emergence of cellular-based therapies represents a major opportunity to improve outcomes in the heavily pretreated and refractory myeloma population.

Dr. Popat on Unmet Needs in Triple-Class Refractory Multiple Myeloma

November 5th 2020

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses unmet needs in triple-class refractory multiple myeloma.

Dr. Lonial on the Advantage of Targeting BCMA in Multiple Myeloma

November 4th 2020

Sagar Lonial, MD, FACP, discusses the advantage of targeting BCMA in multiple myeloma.

BCMA-Targeting Drugs Take Center Stage in Myeloma

November 4th 2020

The treatment landscape for multiple myeloma is poised to enter a new era of innovation with the development of therapies that target B-cell maturation antigen, which is highly expressed on plasma and MM cells.

Dr. Lonial on the Role of BCMA in Multiple Myeloma

November 2nd 2020

Sagar Lonial, MD, FACP, discusses the role of BCMA ​as a target in multiple myeloma.

High Response Rates Heighten Excitement With CAR T-Cell Therapy in Multiple Myeloma

October 30th 2020

Faiz Anwer, MD, discusses the growing role of CAR T-cell therapy in multiple myeloma and areas of unmet need.

MRD Negativity Remains Key Goal in Frontline Myeloma Treatment

October 27th 2020

Andrew Kin, MD, discusses the shift in goals for frontline treatment in multiple myeloma.

Dr. Galligan on Unmet Needs in High-Risk Multiple Myeloma

October 27th 2020

Derek C. Galligan, MD, discusses unmet needs in high-risk multiple myeloma.

Dr. Nagle on the Evolution of Daratumumab Administration in Multiple Myeloma

October 22nd 2020

Sarah Nagle, MD, discusses the evolution of daratumumab administration in multiple myeloma.